Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate.

Fujii T, Shimada K, Asai O, Tanaka N, Fujimoto K, Hirao K, Konishi N.

Pathobiology. 2013;80(3):119-26. doi: 10.1159/000342396. Epub 2013 Jan 11.

2.

Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate.

Wang W, Bergh A, Damber JE.

Prostate. 2009 Sep 15;69(13):1378-86. doi: 10.1002/pros.20992.

PMID:
19507201
4.

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.

Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP.

Cancer. 1998 Jun 1;82(11):2256-61.

PMID:
9610707
5.

Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.

Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Bostwick DG.

J Urol. 1999 Apr;161(4):1229-32.

PMID:
10081875
6.

IL-17 Expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients.

Vykhovanets EV, Maclennan GT, Vykhovanets OV, Gupta S.

Int J Clin Exp Pathol. 2011 Aug 15;4(6):552-65. Epub 2011 Aug 3.

7.
8.

Characterisation of inflammatory cells in benign prostatic hyperplasia.

Anim JT, Udo C, John B.

Acta Histochem. 1998 Nov;100(4):439-49.

PMID:
9842422
9.
10.

Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia.

Jack GS, Brash AR, Olson SJ, Manning S, Coffey CS, Smith JA Jr, Shappell SB.

Hum Pathol. 2000 Sep;31(9):1146-54.

PMID:
11014584
11.

Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis.

Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, Sciarra A.

Eur Urol. 2003 Feb;43(2):164-75.

PMID:
12565775
12.
13.

GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue.

Parsons JK, Nelson CP, Gage WR, Nelson WG, Kensler TW, De Marzo AM.

Prostate. 2001 Sep 15;49(1):30-7.

PMID:
11550208
14.

A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma.

Doganavsargil B, Simsir A, Boyacioglu H, Cal C, Hekimgil M.

BJU Int. 2006 Mar;97(3):644-8.

15.

Immunoreactivity to caspase-3, caspase-7, caspase-8, and caspase-9 forms is frequently lost in human prostate tumors.

Rodríguez-Berriguete G, Galvis L, Fraile B, de Bethencourt FR, Martínez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M.

Hum Pathol. 2012 Feb;43(2):229-37. doi: 10.1016/j.humpath.2011.04.024. Epub 2011 Jul 28.

PMID:
21802116
16.

Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia.

Nägler DK, Krüger S, Kellner A, Ziomek E, Menard R, Buhtz P, Krams M, Roessner A, Kellner U.

Prostate. 2004 Jul 1;60(2):109-19.

PMID:
15162377
17.
18.

Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis.

Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, Maillé P, Allory Y, de la Taille A.

Prostate. 2009 Dec 1;69(16):1774-80. doi: 10.1002/pros.21027.

19.

Clinicopathological features of prostate cancers detected after an initial diagnosis of 'atypical glands suspicious for cancer'.

Zhou M, Magi-Galluzzi C.

Pathology. 2010 Jun;42(4):334-8. doi: 10.3109/00313021003767280.

PMID:
20438405
20.

Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer.

Kryvenko ON, Jankowski M, Chitale DA, Tang D, Rundle A, Trudeau S, Rybicki BA.

Mod Pathol. 2012 Jul;25(7):1023-32. doi: 10.1038/modpathol.2012.51. Epub 2012 Mar 30. Erratum in: Mod Pathol. 2013 Mar;26(3):464.

Supplemental Content

Support Center